Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma

Sica, Gigliola; Lama, Gina; Anile, Carmelo; Geloso, Maria Concetta; Torre, Giuseppe La; Bonis, Pasquale De; Maira, Giulio; Lauriola, Libero; Jhanwar‐Uniyal, Meena; Mangiola, Annunziato

doi:10.3892/ijo_00000822

Cited by 44 publications

(52 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histologic methods to evaluate tumor angiogenesis based on MVD have been found to be an important independent prognostic indicator of patient survival after diagnosis with a brain glioma [10,11]. There are multiple markers available to detect glioma microvasculature.…”

Section: Discussionmentioning

confidence: 99%

The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging

Zhong

Zhou

et al. 2015

European Journal of Radiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging

Zhong

Zhou

et al. 2015

European Journal of Radiology

View full text Add to dashboard Cite

“…Excessive microvascular proliferation and VEGF overexpression were identified in tumor tissues from patients with GBM. Higher intra-tumoral as well as plasma VEGF concentrations were associated with rapid disease progression and presence of early recurrence of GBM (72)(73)(74)(75)(76)(77). Therefore, the evaluation of antiangiogenic and anti-VEGF agents in GBM is highly needed.…”

Section: Inhibition Of Angiogenesis In Gbmmentioning

confidence: 99%

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme

et al. 2017

View full text Add to dashboard Cite

Abstract. Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor in adults with generally dismal prognosis, early clinical deterioration and high mortality. GBM is extremely invasive, characterized by intense and aberrant vascularization and high resistance to multimodal treatment. Standard therapy (surgery, radiotherapy and chemotherapy with temozolomide) has very limited effectiveness, with median overall survival of patients no longer than 15 months. Progress in genetics and epigenetics of GBM over the past decade has revealed various aberrations in cellular signaling pathways, the tumor microenvironment, and pathological angiogenesis. A number of targeted anticancer drugs, such as small-molecule kinase inhibitors and monoclonal antibodies, have been evaluated in clinical trials with newly-diagnosed, as well as recurrent GBM. Unfortunately, to date, only a single antiangiogenic agent, bevacizumab, has been approved for the treatment of recurrent GBM in the USA and Canada. The novel possibilities of cancer immunotherapy, especially immune checkpoint inhibitors, are being evaluated in clinical trials of patients with GBM. The most recent clinical experiences with targeted therapy as well as immunotherapy of GBM are given in this review. The relative lack of success of some of these approaches recently revealed in well-designed randomized clinical trials is also discussed.Glioblastoma multiforme (GBM) belongs to the largest group of primary central nervous system (CNS) tumors, so-called gliomas, which are formed from supporting glial cells in the brain parenchyma (1, 2). GBM represents the most common and most malignant tumor in this class, with an incidence of 3-4/100,000/year (3, 4). GBM is an extremely invasive and difficult to treat tumor, characterized by intense and aberrant vascularization and high resistance to radiotherapy (RT) and chemotherapy (CHT). The current standard of care for patients with newly-diagnosed GBM comprises of neurosurgery and subsequent concomitant chemoradiotherapy by fractionated external-beam RT and systemic temozolomide followed by systemic temozolomide in the adjuvant setting (5). There are only very limited possibilities for the treatment of subsequent recurrences, generally with minimal clinical efficacy (6). Despite intensive multimodal treatment strategies, the median survival of patients with GBM is still 12.1-14.6 months and only 3-5% of patients survive longer than 3 years (7).Enormous progress has been made in the genetics and epigenetics of GBM during the past decade. The Cancer 21Τhis article is freely accessible online.Correspondence to: Jiri Polivka, Department of Neurology, Faculty Hospital Plzen, alej Svobody 80, 304 60, Plzen, Czech Republic. E-mail: polivka@fnplzen.cz Key Words: Glioblastoma multiforme, GBM, targeted therapy, immunotherapy, immune checkpoint inhibitors, PD1 inhibition, CTLA4 inhibition, clinical trials, personalized medicine, review. ANTICANCER RESEARCH 37: 21-34 (2017) [8][9][10][11][12]. The most important genetic...

show abstract

“…The infiltrating tumor cells have the spurious that can invade the adjacent tissue so that the tissue in the distance under 2cm to the tumor is different with the normal tissue and this kind tissue named peritumoral tissue (Mangiola et al, 2007;Sica et al, 2011;Loncarević et al, 2012). Now many studies have found that the expression of surviving evidently upgrade and the caspase 3 downgrade in the tumor, but how about that in the peritumoral tissue?…”

Section: Introductionmentioning

confidence: 99%

Expression of Survivin and Caspase 3 in Oral Squamous Cell Carcinoma and Peritumoral Tissue

Li¹,

Chai²,

Cai³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

This study was conducted to investigate the expression of survivin and caspase 3 in oral squamous cell carcinoma and peritumoral tissue, and possible pathogenesis mechanisms. We used ELISA and western blotting to detect the protein expression levels of survivin and caspase 3 in tissue. In situ hybridization and real-time PCR were applied to assess mRNA expression levels. In this study, 13 tumor samples and 13 peritumoral tissue samples were collected from oral squamous cell carcinoma patients and 10 normal tissue samples obtained from patients without tumor. The result showed that the protein and mRNA expression of survivin in carcinoma was the highest among three types of tissue; following was that in peritumoral tissue. No difference in caspase 3 zymogen between peritumoral tissue and normal tissue could be found, while it was evidently decreased in carcinoma tissue. Activated caspase 3 was detected in normal tissue but could not be identified in peritumoral or carcinoma tissue. Our results indicate that the expression of survivin is apparently elevated in tumoral and peritumoral tissue. Expression of activated caspase 3 was not detected in tumoral tissue and the expression of caspase 3 zymogen was decreased in tumoral tissue. Our findings suggest that survivin may inhibit both synthesis and activation of caspase 3, hence inhibiting cell apoptosis and facililitating eventual development of oral squamous cell carcinoma.

show abstract

Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma

Cited by 44 publications

References 37 publications

The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging

The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme

Expression of Survivin and Caspase 3 in Oral Squamous Cell Carcinoma and Peritumoral Tissue

Contact Info

Product

Resources

About